Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-002526-25
    Sponsor's Protocol Code Number:EP-547-201
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2022-10-07
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2021-002526-25
    A.3Full title of the trial
    Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects with Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    PACIFIC
    A.3.2Name or abbreviated title of the trial where available
    PACIFIC
    A.4.1Sponsor's protocol code numberEP-547-201
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT05525520
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorEscient Pharmaceuticals, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportEscient Pharmaceuticals, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationEscient Pharmaceuticals, Inc.
    B.5.2Functional name of contact pointClinical Trial Information Desk
    B.5.3 Address:
    B.5.3.1Street Address10578 Science Center Drive, Suite 250
    B.5.3.2Town/ citySan Diego
    B.5.3.3Post codeCA 92121
    B.5.3.4CountryUnited States
    B.5.4Telephone number+ 1 (858) 617-8220
    B.5.5Fax number+ 1 (858) 617-8220
    B.5.6E-mailclinicaltrials@escientpharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEP547 Tablet 75mg
    D.3.2Product code EP547
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEP547
    D.3.9.2Current sponsor codeEP547, EP-547
    D.3.9.3Other descriptive nameEP547
    D.3.9.4EV Substance CodeSUB234652
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number75
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEP547 Tablet 25mg
    D.3.2Product code EP547
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEP547
    D.3.9.2Current sponsor codeEP547, EP-547
    D.3.9.3Other descriptive nameEP547
    D.3.9.4EV Substance CodeSUB234652
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Subjects with Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
    E.1.1.1Medical condition in easily understood language
    Subjects with itch (pruritus) due to the reduction or stoppage of bile flow.
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 24.1
    E.1.2Level PT
    E.1.2Classification code 10064190
    E.1.2Term Cholestatic pruritus
    E.1.2System Organ Class 10040785 - Skin and subcutaneous tissue disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    •To assess the efficacy of EP547 compared to placebo on pruritus as assessed by the Worst Itch Numeric Rating Scale (WI-NRS)
    E.2.2Secondary objectives of the trial
    •To assess the efficacy of EP547 compared to placebo on the following:
    − Pruritus-related quality of life using the 5-D Itch Scale
    − Pruritus severity using the Patient Global Impression of Severity (PGI-S)
    − Overall pruritus response to therapy using the Patient Global Impression of Change (PGI-C)
    •To assess the safety and tolerability of EP547
    •To assess the pharmacokinetics (PK) of EP547
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Age 18 to 80 years, inclusive
    2. Has experienced self-reported daily or near-daily moderate to severe pruritus before Screening
    3. Has a mean daily WI-NRS score indicative of moderate to severe pruritus (score ≥4) as recorded using a study-issued electronic device or application (app) during Screening (Day -7 through Day -1); data from at least 4 of the 7 days are required to be considered an acceptable profile
    4. If currently taking medications to treat the cholestatic disorder (obeticholic acid [OCA]), must be on a stable dose for >12 weeks before Screening and plans to maintain the regimen throughout the study
    5. If currently taking a fibrate, must be on a stable dose for >12 weeks before Screening and plans to maintain the regimen throughout the study
    6. Either is not treated with or has been on a stable regimen with any medications to treat pruritus for >4 weeks before Screening and plans to maintain the regimen throughout the study
    7. If female, must be willing to not donate eggs from Screening until 30 days after the last dose of study drug
    8. If male and is not surgically sterile for at least 3 months, must be willing to not donate sperm and must agree to use a barrier method of contraception (eg, condom) during intercourse and at least 1 other acceptable contraceptive measure (eg, hormonal contraceptives, intrauterine device, female surgical sterilization, or abstinence) from Screening through 30 days after the last dose of study drug
    9. Must be able to communicate well with the Investigator, understand and comply with the requirements of the study, and understand and provide written consent
    10. For subjects with concomitant inflammatory bowel disease (IBD):
    a. Colonoscopy (if subject has a colon) or other appropriate endoscopic procedure within 18 months of Day 1 confirming no dysplasia or colorectal cancer
    b. Subjects with Crohn’s disease (CD) must be in remission as defined by a Crohn’s Disease Activity Index (CDAI) <150 at Screening
    c. Subjects with ulcerative colitis (UC) must have a Partial Mayo Scoring Index score≤3 with no individual sub-score exceeding 1 point at Screening
    11. Documented history of PBC that is consistent with the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines (Lindor 2019), defined as having ≥2 of the following 3 factors upon diagnosis:
    a. History of elevated alkaline phosphatase (ALP) levels
    b. Historic positive antimitochondrial antibody (AMA) or AMA-M2 by immunofluorescence, enzyme linked immunosorbent assay (ELISA), or immunoblot or if AMA is negative, positive for PBC-specific antibodies (anti-GP210 and/or anti-SP100)
    c. Liver histology at any point in time consistent with PBC
    12. If currently taking ursodeoxycholic acid (UDCA), must be treated for ≥1 year, and must be on a stable dose of not more than 20 mg/kg/day for ≥12 weeks. If not currently taking UDCA, must not be treated with UDCA within 12 weeks before Screening or plan to be treated with UDCA during the study
    13. Documented history of PSC based on either cholangiography (ie, magnetic resonance cholangiopancreatography, endoscopic retrograde cholangiopancreatography, or percutaneous transhepatic cholangiogram) or if small duct PSC, confirmed by typical histologic evidence of PSC for ≥1 year
    14. If currently taking UDCA, must be treated for ≥1 year, and must be on a stable dose of not more than 23 mg/kg/day for ≥12 weeks. If not currently taking UDCA, must not be treated with UDCA within 12 weeks before Screening or plan to be treated with UDCA during the study.
    E.4Principal exclusion criteria
    1.Pruritus is attributed mainly to any disease unrelated to PBC or PSC
    2.Prior liver transplant or presently listed for transplantation
    3.Is receiving ongoing ultraviolet B (UVB) treatment or plasmapheresis or anticipates receiving such treatments during the study
    4.Evidence of compensated or decompensated cirrhosis based on ANY of the following: Historical liver biopsy demonstrating cirrhosis
    b. Liver stiffness as assessed by a FibroScan® score of ≥16.9 kPa for subjects with PBC or ≥14.4 kPa for subjects with PSC within 6 months of Screening
    c. History or presence of portal hypertension with complications, including known gastric or esophageal varices, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, history of variceal bleeds, or related therapeutic or prophylactic interventions
    5.History of malignancy of any organ system, including but not limited to hepatocellular carcinoma, cholangiocarcinoma, and gall bladder carcinoma, treated or untreated, within the past 5 years (localized squamous cell or basal cell carcinoma of the skin that have been excised or resolved is not exclusionary)
    6.Alternate causes of liver diseases such as hepatic sarcoidosis, alcoholic liver disease, histology confirmed autoimmune hepatitis, overlap hepatitis, or nonalcoholic steatohepatitis (NASH), or uncontrolled viral hepatitis as defined in Protocol
    7.Presence of documented secondary sclerosing cholangitis (eg, ischemic cholangitis, recurrent pancreatitis, intraductal stone disease, severe bacterial cholangitis, surgical or blunt abdominal trauma, recurrent pyogenic cholangitis, choledocholithiasis, toxic sclerosing cholangitis due to chemical agents, or any other cause of secondary sclerosing cholangitis) on prior clinical investigations
    8.Immunoglobulin G4 (IgG4) >4× upper limit of normal (ULN) at Screening or evidence of systemic IgG4-related disease
    9.Current evidence of clinically significant high-grade strictures or presence of biliary stent at Screening
    10.History of recurrent bacterial cholangitis or recent episode within 3 months before Screening
    11.Endoscopic interventions with therapeutic intent such as biliary duct dilation within 3 months before Screening or planned during the study
    12.History of significant small bowel resection or short bowel syndrome
    13.Presence of a concomitant disease or a history of any medical condition that, in the opinion of the Investigator, could pose undue risk to the subject, impede completion of the study procedures, or would compromise the validity of the study measurements
    14.Clinically relevant medical history, physical examination, vital sign, standard 12-lead electrocardiogram (ECG), chemistry, hematology, urinalysis, or coagulation results at Screening beyond what is expected for subjects with a cholestatic disorder that would place the subject at undue risk as deemed by the Investigator
    15.Has any of the following laboratory results at Screening:
    a.Total bilirubin >ULN; total bilirubin >ULN is acceptable for subjects with medically documented Gilbert’s syndrome if direct bilirubin is <0.3 mg/dL
    b.Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5× ULN
    c.ALP >10× ULN
    d.International normalized ratio (INR) >1.3
    e.Platelet count <150,000/μL
    f.Urine albumin to creatinine ratio ≥30 mg/g
    16.Estimated glomerular filtration rate <90 mL/min/1.73 m2 as determined by the Chronic Kidney Disease Epidemiology Collaboration equation at Screening
    17.History of human immunodeficiency virus (HIV) or positive for HIV infection at Screening
    18.Significant history of abuse of drugs, solvents, or moderate alcohol consumption (≥1 serving or unit/day on average for women and ≥2 servings or units/day on average for men) in the past 2 years before Screening
    19.Has received a prohibited medication within 2 weeks or 5 half-lives of Day 1, whichever is longer, as described in Protocol
    20.Participation in any clinical study with an investigational or approved drug/device within 30 days before Screening or is planning to participate in another clinical study with an investigational or approved drug/device while enrolled in this study
    21.History of known or suspected hypersensitivity to any component of the study drug
    22.Female who is pregnant, nursing, or intends to become pregnant during the study
    23.Positive SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) test at Screening
    24.Is directly affiliated with the study at the study site or is an immediate family member (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the study site
    25.Is employed by Escient Pharmaceuticals, Inc., (that is an employee, temporary contract worker, or designee responsible for the conduct of the study) or is an immediate family member of an employee of Escient Pharmaceuticals, Inc.
    26.Subject in the opinion of the Investigator, not suitable to participate in the study
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is the change from baseline in WI-NRS at Week 6.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary analysis will be conducted after the last subject randomized has completed the Double-Blind Treatment Period to determine whether the primary efficacy endpoint of change from baseline in WI-NRS at Week 6 is statistically significant.
    E.5.2Secondary end point(s)
    The secondary efficacy endpoints are:
    • Change from baseline in 5-D Itch Scale
    • The proportion of subjects with improvement in pruritus as defined by PGI-C
    • The proportion of subjects with improvement in pruritus severity from baseline as defined by change in PGI-S
    • The proportion of subjects with a reduction in WI-NRS ≥2 from baseline
    • The proportion of subjects with a reduction in WI-NRS ≥3 from baseline
    • The proportion of subjects with a reduction in WI-NRS ≥4 from baseline
    • The proportion of subjects with WI-NRS <4
    E.5.2.1Timepoint(s) of evaluation of this end point
    The final analysis will be conducted when all randomized subjects have completed the Open-Label Extension Period or are discontinued from the study, and the final database is locked.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    tolerability
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA17
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Israel
    United States
    France
    Netherlands
    Spain
    Belgium
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the date of the last visit of the last participant in the study.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days10
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 52
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 6
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state9
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 16
    F.4.2.2In the whole clinical trial 58
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-11-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-11-29
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2024-09-05
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 20:36:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA